Alnylam Pharmaceuticals Inc (ALNY)vsSeaStar Medical Holding Corporation (ICU)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
ICU
SeaStar Medical Holding Corporation
$2.28
+1.79%
HEALTHCARE · Cap: $8.47M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 421459% more annual revenue ($3.71B vs $881,000). ALNY leads profitability with a 8.5% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
ICU
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Intrinsic value data unavailable for ICU.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
1.7% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : ICU
The strongest argument for ICU centers on Price/Book.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : ICU
The primary concerns for ICU are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while ICU is a value play — different risk/reward profiles.
ALNY carries more volatility with a beta of 0.38 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 33/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
SeaStar Medical Holding Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
SeaStar Medical Holding Corporation (ICU) is an innovative biotechnology company at the forefront of developing advanced therapies for chronic kidney disease. By harnessing proprietary technologies aimed at improving renal function and minimizing the need for invasive interventions, SeaStar addresses significant unmet medical needs within a large and growing market. With a strong emphasis on research and development, the company is well-positioned to drive progress in renal health, supported by strategic partnerships and a commitment to clinical excellence that are anticipated to accelerate the commercialization of its groundbreaking therapeutic solutions.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?